Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1i+RMO in ND-PCNSL and SCNSL
NCT07410520Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib in primary central nervous system lymphoma (PCNSL), secondary central nervous system lymphoma (SCNSL), sponsored by Jiangsu Provincial People's Hospital. Started Feb 2026; status: recruiting.
02
Drugs
orelabrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)secondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on NCT07410520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410520.